New estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute–designated centers, but overall enrollment rates remain low.
Data suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy.
The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
Philips announced the main terms of an agreement it reached in January with the U.S. government on its new sleep apnea machines, which has already cost the company over 360.